Lv11
80 积分 2022-02-27 加入
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已关闭
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1个月前
已完结
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
1个月前
已完结
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus
2个月前
已完结
Developing a machine learning prediction algorithm for early differentiation of urosepsis from urinary tract infection
3个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
3个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
4个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
4个月前
已关闭
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
4个月前
已关闭
A Conceptual Framework for Applying Artificial Intelligence in Project Management
10小时前
已采纳
Unleashing the future of cancer immunotherapy: in silico design of a multi-epitope and mRNA vaccine duo targeting EWSR1-ATF1, EWSR1-CREB1, and PRAME to conquer clear cell sarcoma using immunoinformatics approaches
10小时前
已采纳
β-FeOOH-loaded Juncus effusus as a heterogeneous persulfate activator for rhodamine B degradation
10小时前
已采纳
Non-conforming adaptive mesh refinement for 3-D controlled-source electromagnetic modelling using high-order finite elements
10小时前
待审核
皖公网安备34019202002308
